Association of State-Imposed Restrictions on Gabapentin with Changes in Prescribing in Medicare.

ABSTRACT:

Background

Between August 2016 and July 2018, three states classified gabapentin as a Schedule V drug and nine states implemented prescription drug monitoring program (PDMP) regulation for gabapentin. It is highly unusual for states to take drug regulation into their own hands. The impact of these changes on gabapentin prescribing is unclear.

Objective

To determine the effect of state-imposed regulation on gabapentin prescribing for Medicare Part D enrollees from 2013 to 2018.

Design

Population-based difference-in-difference(DID) analysis study utilizing the Medicare Part D Prescriber Public Use File.

Participants

All eligible Medicare Part D prescribers excluding those outside of the fifty states and the District of Columbia were included in our analysis. Pres

SUBMITTER: Grauer JS 

PROVIDER: S-EPMC9585149 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature